Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004 , a novel oral dasatinib formulation, provides reduced pH‐dependence , minimizing undesirable drug–drug interactions
European Journal of Haematology · 2023
DOI: 10.1111/ejh.14059 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Gunnar Larfors und 6 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Xspray, Nordic CML Study Group.
Abstract (Originalsprache)
Background
Dasatinib and other tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML). However, as a lipophilic weak base, crystalline monohydrate, dasatinib (Sprycel®) is poorly soluble, rendering a pH‐dependent absorption and a highly variable bioavailability. Thus, co‐medication with proton pump inhibitors (PPI) profoundly impairs dasatinib uptake and is clearly recommended against. XS004 is a novel oral immediate release and amorphous solid dispersion (ASD) formulation of dasatinib and is bioequivalent to the original crystalline dasatinib at 30% lower dosages. XS004 is designed to mitigate gastric pH dependency, thus optimizing absorption and bioavailability.
Methods
We investigated the prevalence of dasatinib and PPI co‐medication among chronic‐phase CML patients in a real‐world setting and assessed the plasma pharmacokinetics (PK) of XS004 with and without PPI co‐medication (omeprazole) in healthy volunteers.
Results
Using the Swedish CML and Prescribed Drug Registers, we identified 676 TKI‐treated CML patients; 320 (47%) had been prescribed PPI at some point after CML diagnosis. Among dasatinib‐treated patients, the 2‐year cumulative PPI co‐medication was 24%. Interestingly, the 5‐year overall survival was significantly lower for TKI‐treated CML patients with versus without PPI co‐medication (79% vs. 94%; hazard ratio 3.5; 95% confidence interval, 2.1–5.3; p < .0001). When assessing PK of XS004, neither C max nor area under the plasma concentration curve levels in plasma were significantly altered by the PPI co‐medication.
Conclusion
In conclusion, despite warnings, PPI co‐medication is common among dasatinib‐treated CML patients in a real‐world setting. The new XS004 ASD formulation of dasatinib provided, in contrast to original crystalline dasatinib, superior pH independence with stable bioavailability, thereby minimizing drug–drug interactions. This may improve the long‐term efficacy and tolerability of dasatinib in CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.
- Xspray, Solna, Sweden.
- Department of Pharmaceutical Biosciences, Translational Drug Discovery and Development, Uppsala University, Uppsala, Sweden.
- Karolinska University Hospital and Karolinska Institutet, Department of Hematology, Theme Cancer and Department of Medicine Solna, Stockholm, Sweden.
ORCID-Profile: Gunnar Larfors
Förderung
- Xspray
- Nordic CML Study Group
Zitieren
APA
Larfors, G., Andersson, P., Jesson, G., Liljebris, C., Brisander, M., Lennernäs, H., & Stenke, L. (2023). Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004 , a novel oral dasatinib formulation, provides reduced pH‐dependence , minimizing undesirable drug–drug interactions. European Journal of Haematology. https://doi.org/10.1111/ejh.14059
Vancouver
Larfors G, Andersson P, Jesson G, Liljebris C, Brisander M, Lennernäs H, et al. Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004 , a novel oral dasatinib formulation, provides reduced pH‐dependence , minimizing undesirable drug–drug interactions. European Journal of Haematology. 2023. doi:10.1111/ejh.14059
BibTeX
@article{Larfors2023,
author = {Larfors, Gunnar and Andersson, Per and Jesson, Gérald and Liljebris, Charlotta and Brisander, Magnus and Lennernäs, Hans and Stenke, Leif},
title = {Despite warnings, co‐medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004 , a novel oral dasatinib formulation, provides reduced pH‐dependence , minimizing undesirable drug–drug interactions},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.14059}
}
EUVIMED